Elevai Files Patents For Obesity Lean Mass Preservation; Medtronic Pump Recall
Here is a brief preview of this blast: Two cardiometabolic-related news items have been observed: Elevai Biosciences announced it filed two patent applications for EL-22 (oral myostatin engineered probiotic) as a monotherapy or combination with GLP-1RAs (view press release); and Medtronic announced a voluntary recall of its MiniMed 600/700 series insulin pumps due to shortened battery life issues (view press release). Below, FENIX provides highlights and insights for the respective news items.